2023
DOI: 10.3233/jad-221007
|View full text |Cite
|
Sign up to set email alerts
|

Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer’s Disease

Abstract: Background: Multiple sclerosis (MS) is a prototype neuroinflammatory disorder with increasingly recognized role for neurodegeneration. Most first-line treatments cannot prevent the progression of neurodegeneration and the resultant disability. Interventions can improve symptoms of MS and might provide insights into the underlying pathology. Objective: To investigate the effect of intermittent caloric restriction on neuroimaging markers of MS. Methods: We randomized ten participants with relapsing remitting MS … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 59 publications
0
1
0
Order By: Relevance
“…Rahmani et al. ( 376 ) conducted a pilot study to assess the impact of a twelve weeks intermittent caloric restriction diet on mitigating neuroinflammation in midlife individuals with MS. The study randomly assigned ten participants with relapsing-remitting MS to either a 12-week intermittent calorie restriction (iCR) diet group (n = 5) or a control group (n = 5).…”
Section: Contemporary Approaches In Clinical Trials For Managing Neur...mentioning
confidence: 99%
“…Rahmani et al. ( 376 ) conducted a pilot study to assess the impact of a twelve weeks intermittent caloric restriction diet on mitigating neuroinflammation in midlife individuals with MS. The study randomly assigned ten participants with relapsing-remitting MS to either a 12-week intermittent calorie restriction (iCR) diet group (n = 5) or a control group (n = 5).…”
Section: Contemporary Approaches In Clinical Trials For Managing Neur...mentioning
confidence: 99%